Audited Results for the quarter and year ended on 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.0 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fredun Pharmaceuticals reported strong FY2025-26 results with standalone revenue growing 40% to Rs 63,333 Lakhs (vs Rs 45,171 Lakhs) and PAT surging 60% to Rs 3,321 Lakhs (vs Rs 2,081 Lakhs). EBITDA margins expanded significantly year-on-year. The company declared a 7% final dividend (70 paise per share) and announced a 2:1 bonus share issue subject to shareholder approval. The board also approved increasing authorised share capital from Rs 10 Cr to Rs 50 Cr. The auditor issued an unmodified (clean) opinion on financial results. Key concern: statutory auditors flagged delayed IEPF transfers for unclaimed dividends spanning FY 2015-16 to FY 2017-18, though management stated corrective action is underway.
Strong operational performance with robust revenue and profit growth signals healthy business momentum. The bonus issue will increase share count but signals management confidence. Delayed IEPF compliance is a regulatory risk to monitor but is not critical given the clean audit opinion on financials.